Literature DB >> 24939461

Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.

Shajila Siricilla1, Katsuhiko Mitachi1, Karolina Skorupinska-Tudek2, Ewa Swiezewska2, Michio Kurosu1.   

Abstract

Translocase I (MraY/MurX) is an essential enzyme in growth of the vast majority of bacteria that catalyzes the transformation from UDP-MurNAc-pentapeptide (Park's nucleotide) to prenyl-MurNAc-pentapeptide (lipid I), the first membrane-anchored peptidoglycan precursor. MurX has received considerable attention in the development of new tuberculosis (TB) drugs due to the fact that the MurX inhibitors kill exponentially growing Mycobacterium tuberculosis (Mtb) much faster than clinically used TB drugs. Lipid I isolated from Mtb contains the C50-prenyl unit that shows very poor water solubility; thus, this chemical characteristic of lipid I renders MurX enzyme assays impractical for screening and lacks reproducibility of the enzyme assays. We have established a scalable chemical synthesis of Park's nucleotide-N(ε)-dansylthiourea 2 that can be used as a MurX enzymatic substrate to form lipid I analogues. In our investigation of the minimum structure requirement of the prenyl phosphate in the MraY/MurX-catalyzed lipid I analogue synthesis with 2, we found that neryl phosphate (C10 phosphate) can be recognized by MraY/MurX to generate the water-soluble lipid I analogue in quantitative yield under the optimized conditions. Here, we report a rapid and robust analytical method for quantifying MraY/MurX inhibitory activity of library molecules.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MraY; MurX; MurX inhibitors; Mycobacterium tuberculosis; Translocase I; Water-soluble lipid I

Mesh:

Substances:

Year:  2014        PMID: 24939461      PMCID: PMC4296562          DOI: 10.1016/j.ab.2014.05.018

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  43 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Exit from dormancy in microbial organisms.

Authors:  Jonathan Dworkin; Ishita M Shah
Journal:  Nat Rev Microbiol       Date:  2010-10-25       Impact factor: 60.633

3.  In vitro antimycobacterial activities of capuramycin analogues.

Authors:  Venkata M Reddy; Leo Einck; Carol A Nacy
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

4.  Slow binding inhibition of phospho-N-acetylmuramyl-pentapeptide-translocase (Escherichia coli) by mureidomycin A.

Authors:  P E Brandish; M K Burnham; J T Lonsdale; R Southgate; M Inukai; T D Bugg
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

5.  Improved synthesis of capuramycin and its analogues.

Authors:  Yong Wang; Shajila Siricilla; Bilal A Aleiwi; Michio Kurosu
Journal:  Chemistry       Date:  2013-09-06       Impact factor: 5.236

6.  N Glycolylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacterium spp. is altered by drug treatment.

Authors:  Sebabrata Mahapatra; Hataichanok Scherman; Patrick J Brennan; Dean C Crick
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

7.  Synthesis of ureidomuraymycidine derivatives for structure-activity relationship studies of muraymycins.

Authors:  Bilal A Aleiwi; Christopher M Schneider; Michio Kurosu
Journal:  J Org Chem       Date:  2012-04-06       Impact factor: 4.354

8.  Essential metabolites of Mycobacterium tuberculosis and their mimics.

Authors:  Gyanu Lamichhane; Joel S Freundlich; Sean Ekins; Niluka Wickramaratne; Scott T Nolan; William R Bishai
Journal:  mBio       Date:  2011-02-01       Impact factor: 7.867

9.  One-pot protection-glycosylation reactions for synthesis of lipid II analogues.

Authors:  Katsuhiko Mitachi; Priya Mohan; Shajila Siricilla; Michio Kurosu
Journal:  Chemistry       Date:  2014-03-12       Impact factor: 5.236

10.  Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis.

Authors:  Boris V Nikonenko; Venkata M Reddy; Marina Protopopova; Elena Bogatcheva; Leo Einck; Carol A Nacy
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

View more
  16 in total

1.  Substrate Tolerance of Bacterial Glycosyltransferase MurG: Novel Fluorescence-Based Assays.

Authors:  Katsuhiko Mitachi; Hyun Gi Yun; Cody D Gillman; Karolina Skorupinska-Tudek; Ewa Swiezewska; William M Clemons; Michio Kurosu
Journal:  ACS Infect Dis       Date:  2019-12-11       Impact factor: 5.084

2.  DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.

Authors:  Katsuhiko Mitachi; Rita G Kansal; Kirk E Hevener; Cody D Gillman; Syed M Hussain; Hyun Gi Yun; Gustavo A Miranda-Carboni; Evan S Glazer; William M Clemons; Michio Kurosu
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

3.  N-Acetylglucosamine-1-Phosphate Transferase, WecA, as a Validated Drug Target in Mycobacterium tuberculosis.

Authors:  Stanislav Huszár; Vinayak Singh; Alica Polčicová; Peter Baráth; María Belén Barrio; Sophie Lagrange; Véronique Leblanc; Carol A Nacy; Valerie Mizrahi; Katarína Mikušová
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Fluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors.

Authors:  Katsuhiko Mitachi; Shajila Siricilla; Dong Yang; Ying Kong; Karolina Skorupinska-Tudek; Ewa Swiezewska; Scott G Franzblau; Michio Kurosu
Journal:  Anal Biochem       Date:  2016-08-13       Impact factor: 3.365

5.  Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.

Authors:  Nada Lelovic; Katsuhiko Mitachi; Junshu Yang; Maddie R Lemieux; Yinduo Ji; Michio Kurosu
Journal:  J Antibiot (Tokyo)       Date:  2020-05-29       Impact factor: 2.649

6.  Chemoenzymatic syntheses of water-soluble lipid I fluorescent probes.

Authors:  Katsuhiko Mitachi; Shajila Siricilla; Lada Klaic; William M Clemons; Michio Kurosu
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

7.  Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor.

Authors:  Katsuhiko Mitachi; David Mingle; Wendy Effah; Antonio Sánchez-Ruiz; Kirk E Hevener; Ramesh Narayanan; William M Clemons; Francisco Sarabia; Michio Kurosu
Journal:  Angew Chem Int Ed Engl       Date:  2022-06-10       Impact factor: 16.823

8.  Stereocontrolled Total Synthesis of Muraymycin D1 Having a Dual Mode of Action against Mycobacterium tuberculosis.

Authors:  Katsuhiko Mitachi; Bilal A Aleiwi; Christopher M Schneider; Shajila Siricilla; Michio Kurosu
Journal:  J Am Chem Soc       Date:  2016-09-26       Impact factor: 15.419

9.  Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.

Authors:  Shajila Siricilla; Katsuhiko Mitachi; Bajoie Wan; Scott G Franzblau; Michio Kurosu
Journal:  J Antibiot (Tokyo)       Date:  2014-10-01       Impact factor: 2.649

Review 10.  Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics.

Authors:  Ken-Ichi Kimura
Journal:  J Antibiot (Tokyo)       Date:  2019-10-04       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.